MedTrace Logo

Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART

NCT02249962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12011

Last updated 2021-03-12

No results posted yet for this study

Summary

To characterize safety, durability, antiretroviral treatment (ART) resistance, and clinical outcomes for mothers and infants exposed to the efavirenz-based Option B+ regimen for Prevention of Mother to Child Transmission (PMTCT) and HIV treatment in Malawi.

Conditions

  • HIV
  • Infant Exposure to Efavirenz

Sponsors & Collaborators

  • Ministry of Health and Population, Malawi

    collaborator OTHER_GOV

  • University of North Carolina

    collaborator OTHER

  • Lighthouse Trust

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Mina C Hosseinipour, MD, MPH · UNC Project- Malawi

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02249962 on ClinicalTrials.gov